Literature DB >> 32215676

[Legal aspects of quality assurance : Example of operative intravitreal injection therapy].

Reinhold Preißler1, Eva Hansmann2, Klaus-Dieter Schnarr3, Bernd Bertram4, Focke Ziemssen5.   

Abstract

BACKGROUND: In the legal evaluation of medical treatments it is important to know which legal and contractual regulations apply.
OBJECTIVE: This article discusses in which context treatment errors play a role and are identified as such.
MATERIAL AND METHODS: Relevant German legal framework conditions are discussed and examples with reference to intravitreal injection therapy are given.
RESULTS: The civil law treatment contract between physician and patient results in the medical obligations of a service contract. As a consequence, the physician is obliged to provide the patient with treatment according to the current generally accepted professional standard, including information obligations, the certainty of a diagnosis, the execution of treatment and aftercare. Before claims for compensation and damages for pain and suffering can be enforced, proof of a treatment error and the causal connection must be provided. In court, mostly expert opinions are used to assess what the professional standard is and whether the physician was sufficiently qualified, whether informed consent and documentation met the legal requirements and whether a (gross) treatment error must be assumed. The Patients' Rights Act emphasizes the importance of an open error culture by requiring a practitioner to inform patients of third party/own treatment errors on request or in order to avert health risks, if circumstances are discernible to the practitioner that justify the assumption of a treatment error.
CONCLUSION: Although ophthalmologists cannot guarantee healing or success but only the treatment, there are many medical obligations for intravitreal therapy. Increased standards of quality assurance can be implemented within the framework of selective contracts.

Entities:  

Keywords:  Automatic analysis; Benchmarking; Data transfer; Statement certainty; Treatment error

Mesh:

Year:  2020        PMID: 32215676     DOI: 10.1007/s00347-020-01062-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  9 in total

Review 1.  [Ophthalmological assessment in the Severely Handicapped Persons Act and in blindness : Statement of the Professional Association of Ophthalmologists Germany, the German Ophthalmological Society processed by the Joint Commission on Law. Status January 2017].

Authors: 
Journal:  Ophthalmologe       Date:  2017-08       Impact factor: 1.059

Review 2.  [Quality assurance of optical coherence tomography for diagnostics of the fundus : Positional statement of the BVA, DOG and RG].

Authors: 
Journal:  Ophthalmologe       Date:  2017-07       Impact factor: 1.059

3.  [Development of the Physician-patient Relationship in Germany during the Last Years from the Perspective of the Heads of Chambers and KVs].

Authors:  C Thielscher; B Schulte-Sutrum
Journal:  Gesundheitswesen       Date:  2014-10-14

Review 4.  [Experienced quality assurance in the IVOM structural contract of the AOK‑BW : A practical example].

Authors:  H Agostini; A Pfaff; V Graeff; L Hesse; F Ziemssen
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

Review 5.  [IVOM quality assurance in Westfalen-Lippe : Structure of quality assurance and results of the pilot study Q-VERA].

Authors:  J Stasch-Bouws; S M Eller-Woywod; S Schmickler; J Inderfurth; P Hoffmann; C Ohlmeyer; B Kammering; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

6.  [Delayed treatment initiation of more than 2 weeks. Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study)].

Authors:  F Ziemssen; T Bertelmann; U Hufenbach; M Scheffler; S Liakopoulos; S Schmitz-Valckenberg
Journal:  Ophthalmologe       Date:  2016-02       Impact factor: 1.059

7.  [Regional Differences in the Care of Patients with Neovascular Age-Related Macular Degeneration, Based on the Non-Interventional OCEAN Study].

Authors:  F Ziemssen; U Hufenbach; A Wiedon; M Scheffler; T Bertelmann
Journal:  Klin Monbl Augenheilkd       Date:  2016-07-25       Impact factor: 0.700

8.  [Intravitreal injections of medications in Germany. Contract situation and legal conditions].

Authors:  F Ziemssen; P Wiedemann; A Kampik; F Holz; K U Bartz-Schmidt
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

9.  [Baseline diagnostics and initial treatment decision for anti-vascular endothelial growth factor treatment in retinal diseases : Comparison between results by study physician and reading centers (ORCA/OCEAN study)].

Authors:  Christian K Brinkmann; Petrus Chang; Tina Schick; Britta Heimes; Jessica Vögeler; Birgit Haegele; Bernd Kirchhof; Frank G Holz; Daniel Pauleikhoff; Focke Ziemssen; Sandra Liakopoulos; Georg Spital; Steffen Schmitz-Valckenberg
Journal:  Ophthalmologe       Date:  2019-08       Impact factor: 1.059

  9 in total
  1 in total

Review 1.  [Value and formats of quality assurance : Ophthalmology and intravitreal therapy between reality and wishful thinking].

Authors:  Nicole Eter; Daniel Pauleikhoff; Hansjürgen Agostini; Monika Fleckenstein; Focke Ziemssen
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.